On Monday, Novavax, Inc. (NASDAQ: NVAX) opened higher 2.52% from the last session, before settling in for the closing price of $3.97. Price fluctuations for NVAX have ranged from $3.53 to $11.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 513.29% over the last five years. Company’s average yearly earnings per share was noted 86.44% at the time writing. With a float of $132.98 million, this company’s outstanding shares have now reached $139.51 million.
The firm has a total of 1543 workers. Let’s measure their productivity.
Novavax, Inc. (NVAX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Novavax, Inc. is 4.98%, while institutional ownership is 56.86%.
Novavax, Inc. (NVAX) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2023, the company posted -$1.44 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.45) by -$0.99. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.44% per share during the next fiscal year.
Novavax, Inc. (NASDAQ: NVAX) Trading Performance Indicators
Check out the current performance indicators for Novavax, Inc. (NVAX). In the past quarter, the stock posted a quick ratio of 0.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.54, a number that is poised to hit -0.92 in the next quarter and is forecasted to reach -0.05 in one year’s time.
Technical Analysis of Novavax, Inc. (NVAX)
Analysing the last 5-days average volume posted by the [Novavax, Inc., NVAX], we can find that recorded value of 3.11 million was lower than the volume posted last year of 7.6 million. As of the previous 9 days, the stock’s Stochastic %D was 22.51%. Additionally, its Average True Range was 0.25.
During the past 100 days, Novavax, Inc.’s (NVAX) raw stochastic average was set at 21.35%, which indicates a significant decrease from 27.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 30.62% in the past 14 days, which was lower than the 82.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.69, while its 200-day Moving Average is $6.09. Now, the first resistance to watch is $4.16. This is followed by the second major resistance level at $4.26. The third major resistance level sits at $4.38. If the price goes on to break the first support level at $3.94, it is likely to go to the next support level at $3.82. Should the price break the second support level, the third support level stands at $3.72.
Novavax, Inc. (NASDAQ: NVAX) Key Stats
There are currently 139,953K shares outstanding in the company with a market cap of 569.60 million. Presently, the company’s annual sales total 983,710 K according to its annual income of -545,060 K. Last quarter, the company’s sales amounted to 291,340 K and its income totaled -178,390 K.
